Thoracic aortic stent grafting: Is it ready for prime time?  by Gleason, Thomas G.
Editorials Gleason
ED
ITO
RIA
LThoracic aortic stent grafting: Is it ready for prime time?
Thomas G. Gleason, MDFrom the Department of Surgery, Division
of Cardiothoracic Surgery, Northwestern
University Feinberg School of Medicine,
Chicago, IL.
Received for publication Dec 13, 2005; ac-
cepted for publication Dec 13, 2005.
Address for reprints: Thomas G. Gleason,
MD, Northwestern University Feinberg
School of Medicine, 201 E. Huron St., Galter
10-105, 201 East Huron St, Chicago, IL
60611-3056 (E-mail: tgleason@nmh.org).
J Thorac Cardiovasc Surg 2006;131:16-8
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgery
See related article on page 131.doi:10.1016/j.jtcvs.2005.09.008
16 The Journal of Thoracic and CardiovRicco and colleagues1 are to be congratulated for their comprehensive report-ing of the operative results of the French thoracic aortic stent graftingexperience over the 2-year period from 1999 through 2001. This is the only
report of its kind that depicts the results of an entire country’s experience. It was
designed by the French National Health Insurance Fund, with the data verified by
third-party advisors. The report is both timely and provocative in the wake of the US
Food and Drug Administration’s recent approval of the use of the Gore TAG
endograft for thoracic aortic aneurysms in an elective setting.
A total of 166 thoracic aortic stent grafts were placed in 29 centers, with no
center performing more than 15 cases, and most centers inserting 5 or less grafts
in the 2-year period. Although presumably capturing all or most thoracic aortic
stent-grafting cases performed in France during the time period, the report is
limited in both its scope and its analysis. The most relevant limitations are the
report’s retrospective nature and its inherent lack of follow-up data. Despite
these flaws, the article reveals several important findings. Devices used included
both industrial products (Gore [53%], Medtronic [32%], Stenford [4%], and
Boston Scientific [0.5%]) and custom-made grafts designed by the implanting
physicians (10%), a profile that is representative of trends around the world. The
morbidity and mortality rates by device implanted or by physician specialty (ie,
surgeon, radiologist, or cardiologist) are not provided. The overall mortality and
major complication rates were significant at 10% and 29%, respectively (al-
though 3 patients were not followed to 30 days). Type I or II endoleaks occurred
in 16.3%, but among patients who had proximal descending thoracic aortic
coverage (23 patients), 26% had a type I endoleak. Fifteen of the 23 had
concomitant left subclavian artery transposition. All type I leaks required
additional intervention either by means of open or endovascular techniques. The
details of how and when these endoleaks were diagnosed are not provided. Two
cases of proximal stent graft migration occurred, but it is not clear whether this
migration occurred intraoperatively or postoperatively. None of the type II
endoleaks (18 cases) were treated. Follow-up is not provided to demonstrate the
natural history or prognosis of these type II leaks in this series. Type III
endoleaks were not reported, although 3 of the type I leaks apparently occurred
between 2 stent grafts. Paraplegia occurred in 6 (3.6%) patients. Although the
anatomic detail and extent of aneurysm coverage is not provided for the patients
who had paraplegia, 3 had concomitant abdominal aortic aneurysm repairs. Five
of these 6 patients died. Neither spinal drainage nor perioperative evoked
potential monitoring was used in any case, a practice that would seem prudent
in high-risk cases. Chronic type B aortic dissection was present in 20% of the
cases, and the mortality rate among this cohort was 15.2%. There were 17 cases of
acute traumatic disruption treated with endografting, with a mortality rate of 6%.
There were 3 cases of postoperative aortoesophageal or aortotracheal fistulae, a
complication that is less common after conventional open repair. Endografts were
placed in 3 patients with known septic aneurysms, and 2 of these patients died
within 30 days. Finally, the authors appropriately highlight the fact that at least 17%
of the aneurysms treated among the entire group were smaller than 50 mm, and the
mortality rate among these cases was 5%.
In summary, the report by Ricco and colleagues1 provides an unbiased glance of
what the results of this new technology are likely to be when applied across a wide
range of pathology, experience, and expertise. Despite the many advances in the
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aorta remains at a developmental phase. Current devices are
limited in their utility because of (1) their own structural
flaws, (2) the limited array of graft sizes available, (3) the
inherent difficulty in covering the acute angulations of the
aortic arch and tortuous thoracic aortic segments, and (4) the
lack of widespread expertise in endovascular techniques.
There are no devices currently available that are uniformly
applicable to the array of descending thoracic aortic dis-
eases. Despite this realization, stent grafting clearly has an
evolving role in thoracic aortic surgery, and results like
these are encouraging.
In evaluating the current state of the art, it behooves us
to scrutinize the results by comparing them with those of
conventional techniques performed by major centers
around the world. It is these results that should be used as
the benchmark for the valuation of endovascular repair.
For example, in 2004, Coselli and associates2 reported
their experience after 387 consecutive open repairs of the
descending thoracic aorta (emergency and elective re-
pairs) with an overall operative mortality rate of 4.4%.
More than half of this series included patients in whom
the entire descending thoracic aorta (extents A, B, and C)
was replaced with a mortality rate of only 4%. Contrarily,
in this French endograft experience none of the patients
had coverage of the entire thoracic aorta (extents A, B,
and C), yet the overall hospital mortality rate was 10%.
One question for the cardiothoracic community is
whether we should be striving to meet outcome targets
set by large-volume centers using conventional strategies
before embracing a new technology that at first glance
might not generate results that are improved over those of
conventional strategies. There is no doubt that stent graft-
ing can yield a seemingly good outcome with very little
morbidity in certain settings, and this has been shown in
other small series. Whether this technique should be used
for aortic dissections, transections, small aneurysms
(50 mm), or septic aneurysms is still in question, with
very little current data to support the practice.
Several questions remain unanswered by the current
primary literature. Volume rendering and 3-dimensional
reconstruction imaging modalities have not been stan-
dardized, and therefore their accuracy in the prediction of
aortic diameter and shape to be used in planning stent-
grafting procedures remains anecdotal, such that sizing
strategies are sometimes imprecise. The optimal degree
of upsizing a graft diameter relative to the target landing
site’s diameter is not always clear and differs depending
on device manufacturer and composition of the en-
dografts. Similarly, the minimum landing zone length is
still not clear, particularly in or near the arch. We do not
know how much arch angulation is too much, nor do we
know whether left subclavian coverage will be durable,
The Journal of Thoracparticularly when the landing zone is only 2 cm or less of
graft length. Similarly, we do not know whether trans-
position will provide a better long-term result in cases of
left subclavian coverage than simple coverage without
transposition or bypass. Given the extent of angulation of
the thoracic aorta, it is unclear whether modular seg-
mented endografts are inferior or superior to single-
segment endografts. We do not know the long-term effect
of the persistent radial tension applied to the aortic wall
by these endografts or whether the radial tension predis-
poses to aortoesophageal or aortotracheal fistulae in seg-
ments of aorta that are adjacent to these structures.
Endoleaks are another major conundrum. Type I en-
doleaks compromise the integrity of a repair and predispose
to aneurysm disruption, resulting in little benefit over ex-
pectant management. The clinical relevance and effect of
type II and III endoleaks are less clear, particularly in the
midterm and long term. Little is known about the safety and
efficacy of treating thoracoabdominal aortic disease with
stent grafts that cover mesenteric vessels. Several groups,
including my own, are beginning to test these waters.
The risks of paraplegia appear to be lower in certain
series, but not when comparing this current series with that
of Coselli and associates.2 It seems prudent to extend and
apply what we have learned about reducing the risks of
paraplegia during conventional open repair to stent grafting.
To date, guidelines for applying adjunctive measures have
not been created. It is not clear which subset of patients will
benefit from interventions like cerebrospinal fluid drainage
or evoked potential monitoring to help prevent paraplegia
after stent grafting.
Finally are the issues of credentialing and future inves-
tigation. Recently, a taskforce was established by the Soci-
ety of Thoracic Surgeons that has suggested a credentialing
protocol to help ensure patient safety.3 This concept is one
based on the voluntary participation of surgeons. Important
questions remain as to how the credentialing process should
be organized and controlled and what the role of the pro-
fessional societies, the corporations that make the devices,
the hospitals or universities, and the government should be
in this process. Rigorous clinical trialing must continue to
protect patients and ensure that we continue to strive to
achieve better results with endografts than can be achieved
with open conventional procedures rather than be compla-
cent with the current state of the art simply because the
deployment of these endografts is seemingly straightfor-
ward, an enticing prospect for many physicians whose prac-
tices are in search of additional revenue sources. The an-
swers to many of these questions remain elusive. Ricco and
colleagues1 should be commended in their reporting of
these French data. Despite the fact that these data are 3 years
old, the report adds significantly to our understanding of
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technology.
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